<DOC>
	<DOC>NCT02743494</DOC>
	<brief_summary>The purpose of this study is to determine whether nivolumab will improve overall survival, disease-free survival, or both compared with placebo.</brief_summary>
	<brief_title>Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal or Gastroesophageal Junction Cancer</brief_title>
	<detailed_description />
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Diagnosed with Stage II/III carcinoma of the esophagus or gastroesophageal junction Completed preoperative chemo radiotherapy followed by surgery Diagnosed with residual pathologic disease after being surgically rendered free of disease with negative margins following complete resection Diagnosed with cervical esophageal carcinoma Diagnosed with Stage IV resectable disease Did not receive concurrent chemoradiotherapy prior to surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>